Navigation Links
BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
Date:2/5/2013

imilar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the proposed NDA submission for, and FDA review of, BNX) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences logo is a trademark owned by BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG.  All other trademarks and tradenames are owned by their respective owners.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
2. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
3. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
6. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
7. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
8. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. BioDelivery Sciences Announces $40 Million Registered Financing
10. BioDelivery Sciences Announces Completion of BNX Safety Study
11. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)...  NeuroSigma, Inc. (NeuroSigma), a California ... non-invasive Monarch ™ eTNS™ Therapy for ... that enrollment has begun in a pediatric open label ... therapy for the treatment of Lennox-Gastaut Syndrome (LGS). ... View-UCLA Medical Center in Sylmar, California ...
(Date:7/22/2014)... England , July 22, 2014 ... development and device company focused on solid dose ... its novel solid formulation of octreotide acetate achieved ... it with the currently marketed liquid product (Sandostatin®). ... transfer the formulation production process to a contract ...
(Date:7/21/2014)... N.J. , July 21, 2014  Champions Oncology ... advanced technology solutions and services to personalize the development ... report its financial and operational results for the fourth ... Thursday, July 24, 2014, after market close. ... the results that day at 4:30 p.m. EDT (1:30 ...
Breaking Medicine Technology:Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2
... 10, 2011 USANA Health Sciences, Inc. (NYSE: ... nutritional gaps are common in the average American diet and ... those gaps.  However, USANA scientists and advising physicians caution that ... Dietary Guidelines for Americans, 2010 and ...
... MATEO, Calif., Feb. 10, 2011 AlphaDetail, a leader ... biotech industries, reported a 30% increase in revenue in ... time in the company,s history. "Our clients ... provides the marketing research solutions that get at the ...
Cached Medicine Technology:USDA Recognizes Benefit of Supplements in New Dietary Guidelines But Doesn't Go Far Enough 2AlphaDetail Revenue Soars 30% in 2010 2
(Date:7/22/2014)... 2014 Visitors to the Radiometer booth ... July 29-31) will have the opportunity to learn from ... errors. Radiometer will host two sessions of each presentation ... Individualized Quality Control Plan (IQCP) for Blood Gas Testing, ... Sy Albakri, PhD, Clinical and Scientific Affairs Manager, Radiometer ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Recently, 2014quinceaneradresses.com, ... has announced its latest assortment of blue and ... promotional prices on these special Quinceanera gowns, hoping to ... before July 30 can get a discounted price, up ... very glad to announce these new items. As one ...
(Date:7/22/2014)... July 22, 2014 MyDiettogo ... well as community discussion forums, to make it easier ... health. Customers now can track their Diet-to-Go meals, change ... journey, all from their computer or smart phone. Diet-to-Go ... staff Nutritionist and Certified Health Coach. , According to ...
(Date:7/22/2014)... 22, 2014 Industry-leading health business information ... release of Specialty Pharmacy Trends and Strategies: 2014 ... provides a comprehensive overview of the current state of ... strategies and tactics for:, , Specialty ... utilization concerns — including details of coinsurance levels by ...
(Date:7/22/2014)... 22, 2014 To help offset the ... Therapy Training Institute of Miami is reducing the ... award-winning model Brief Strategic Family Therapy™. To implement ... a variety of funding sources, but those opportunities seem ... situation we want to help relieve somehow,” said the ...
Breaking Medicine News(10 mins):Health News:Radiometer Features Booth Presentations On IQCP and Blood Gas Preanalytics at the 2014 AACC Clinical Lab Expo 2Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2Health News:Diet-to-Go Introduces New Online and Mobile Weight-Loss Tools, with Apps for iPhone and Android 2Health News:Latest Edition of Annual Book Provides Comprehensive Overview of the Specialty Pharmacy Arena 2Health News:FTTIM Makes Brief Strategic Family Therapy Training a Little More Affordable 2Health News:FTTIM Makes Brief Strategic Family Therapy Training a Little More Affordable 3
... combines bone marrow removal and injection of a hormone ... locations in the body, it was reported by Yale ... "This could radically change the way patients are currently ... traumatic long bone fractures," said senior author Agns ...
... AUBURN HILLS, Mich., Feb. 14 Armed with the ... a hefty price tag, a,major automotive company has taken ... The program is 10 times more effective and ... and is expected to,translate into significant healthcare expense savings., ...
... this problem is an important step before moving on to ... major concern with using stem cells to treat disease has ... cells might cause cancer, but now a group of scientists ... groups of researchers -- one in Japan and one in ...
... Goes to Conference Committee Next Before Final Version is,Voted ... repayment,program for professions of "national need" will include occupational,therapists ... agreed to by the,Senate. AOTA staff worked fast and ... late last week. AOTA was able to have Representative ...
... Eye Care & Dental Professionals Kick off Year-Long Initiative, ... in Buffalo,NY, the world is about to become brighter. ... by volunteers recently at the first of,Davis Vision,s 2008 ... Bills, the event attracted 100 children,ages 5 through 16 ...
... Boston Scientific,Corporation (NYSE: BSX ) today announced that ... Venous Access businesses to Avista Capital,Partners for $425 million ... December 13, 2007., The Company expects to record ... quarter of 2008 in connection with the,transaction., "The ...
Cached Medicine News:Health News:Chrysler Goes Holistic to Revolutionize Back Pain Care in the Workplace 2Health News:Chrysler Goes Holistic to Revolutionize Back Pain Care in the Workplace 3Health News:Scientists Show Stem Cells Don't Cause Cancer 2Health News:Scientists Show Stem Cells Don't Cause Cancer 3Health News:AOTA Gets Profession Addressed on House Floor in Federal Loan Repayment Bill 2Health News:Davis Vision, United Concordia Free Clinic Promotes Children's Eye and Dental Health 2Health News:Davis Vision, United Concordia Free Clinic Promotes Children's Eye and Dental Health 3Health News:Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners 2Health News:Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners 3Health News:Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners 4
... Vitrectomy Lenses are a family of single-use direct ... of a particular region of the retinal surface ... less than 1 gram and is formed and ... of a human cornea. Lenses come in boxes ...
... The AFX Lens is a ... use in an air-filled eye. ... as a primary air-fluid exchange ... and sutureless design make it ...
... The Chalam 30° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
Medicine Products: